Using the Swedish Heart Failure Registry to improve treatment for reduced ejection fraction
Official title: Optimizing HF Treatment by Registry Screening for Need of Implementation and Referral to the Optimization Outpatient Clinic
Run by Region Stockholm · NCT07154758 · Data updated 2026-11-12
This project will test whether screening people with HFrEF in the Swedish Heart Failure Registry can increase starts or dose‑ups of guideline heart‑failure medicines, iron testing, and referrals for devices or physiotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Region Stockholm Government |
| Locations | 6 sites (Gothenburg and 5 other locations) |
| Status | Recruiting |
| Started | May 1, 2024 |
| Main results expected | June 30, 2026 |
| Study ends | June 30, 2026 |
| Registry record updated | September 4, 2025 |
| Trial ID | NCT07154758 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with heart failure with reduced ejection fraction (EF ≤40%), HF duration >6 months, registered in SwedeHF (or with hospital access after Jan 1, 2023), and able to give informed consent for the screening arm.
✕Probably not a fit
Patients already optimized on guideline‑directed therapy, those not recorded in the Swedish registry, unable to consent, or judged unlikely to comply with procedures may not gain benefit from the intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The project uses the SwedeHF registry to screen patients with heart failure and reduced ejection fraction (EF ≤40%) for gaps in guideline‑directed medical therapy, iron deficiency screening/treatment, device indications (CRT/ICD), and physiotherapy referral. Identified patients in the screening arm are flagged for implementation actions and compared with a sex‑ and age‑matched control group at participating centers. The primary outcome is a composite of at least one drug initiation or uptitration (SGLT2i, MRA, BB, RASi/ARNi, iv iron), iron deficiency screening, or referral for device therapy. Eligible participants have HFrEF for more than six months and are registered in SwedeHF or have hospital access after January 1, 2023, with informed consent required for the screening arm.
Why it matters
Potential benefit: If successful, more people with HFrEF could receive recommended medications, iron treatment, and device referrals, which may lower hospitalizations and improve clinical outcomes.
How similar studies have gone: Registry‑based quality improvement and implementation programs in cardiovascular care have previously increased uptake of guideline therapies, but randomized data specifically using SwedeHF for this multifaceted approach are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Registration in SwedeHF with an index date after January 1st 2023 for the screening arm. For controls, hospital access after January 1st 2023. * HF duration \>6 months to ensure that patients had time to go through the treatment optimization process as recommended by the guidelines. * HF with reduced EF (HFrEF) defined as categorical or continuous EF ≤40% * Capable of giving signed informed consent (for the screening arm) Exclusion Criteria: * Under optimization of HF therapy * In judgment of the investigator unlikely to understand or comply with study procedures Control population is sex and age matched with the SwedeHF screening arm (1:1)
Where it's running
-
Sahlgrenska Universitetssjukhuset
Gothenburg, Sweden Recruiting -
Hemse vårdcentral
Hemse, Sweden Recruiting -
Länssjukhuset Ryhov
Jönköping, Sweden Recruiting -
Karolinska University Hospital
Stockholm, Sweden Recruiting -
St Görans hospital
Stockholm, Sweden Recruiting -
Södersjukhuset
Stockholm, Sweden Recruiting
Study contacts
- Study coordinator: Gianluigi Savarese, MD PhD
- Email: gianluigi.savarese@ki.se
- Phone: +46 8-524 870 75
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
NT-proBNP–guided heart failure screening for people 65+ in rural China
This study tests whether using NT-proBNP blood tests to guide heart failure screening in adults 65 and older in rural China can find unrecognized heart problems more effectively than symptom-based screening.
-
Voice-based detection of heart failure deterioration using Noah Labs Vox
This study tests whether a voice-analysis app can flag worsening heart failure in adults by comparing its alerts to standard weight-based monitoring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.